ZUG, Switzerland April 1, 2025 Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing innovative therapies for bradykinin-mediated diseases, has announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant. This designation is aimed at facilitating the PHVS
Deucrictibant is a novel oral bradykinin B2 receptor antagonist designed to address the significant unmet medical needs of patients suffering from these debilitating conditions. HAE and AAE-C1INH are characterised by recurrent episodes of severe swelling, which can lead to pain and critical complications, including airway obstruction.
The orphan designation is particularly significant, as it underscores both the rarity of the target conditions and the potential impact of effective treatment options. Orphan designation provides various incentives for pharmaceutical companies, including extended market exclusivity, fee reductions for regulatory procedures, and, importantly, support for the development of treatments that may not otherwise be financially viable.
We are thrilled to receive orphan designation for deucrictibant, as it aligns with our mission to deliver innovative solutions for patients in need, said a spokesperson for Pharvaris. This recognition from the European Commission not only validates our efforts but also enhances our commitment to bringing a new treatment option to the market for those suffering from bradykinin-mediated angioedema.
As of the latest market data, Pharvaris s share price stands at $15.70, reflecting investor interest in the company’s promising pipeline of therapeutics.
The grant of orphan designation is expected to accelerate the development and potential marketing of deucrictibant within the European Union, which could significantly alleviate suffering for countless patients and their families.
Comments